Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catheter Precision (VTAK) Current Deferred Revenue (2017 - 2021)

Catheter Precision (VTAK) has disclosed Current Deferred Revenue for 5 consecutive years, with $1.8 million as the latest value for Q2 2021.

  • On a quarterly basis, Current Deferred Revenue fell 3.87% to $1.8 million in Q2 2021 year-over-year; TTM through Jun 2021 was $1.8 million, a 3.87% decrease, with the full-year FY2020 number at $1.8 million, down 45.42% from a year prior.
  • Current Deferred Revenue was $1.8 million for Q2 2021 at Catheter Precision, up from $1.8 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $3.3 million in Q4 2019 to a low of $1.7 million in Q4 2017.
  • A 5-year average of $1.9 million and a median of $1.8 million in 2020 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: soared 91.53% in 2019, then tumbled 45.42% in 2020.
  • Catheter Precision's Current Deferred Revenue stood at $1.7 million in 2017, then increased by 0.53% to $1.7 million in 2018, then skyrocketed by 91.53% to $3.3 million in 2019, then crashed by 45.42% to $1.8 million in 2020, then decreased by 0.78% to $1.8 million in 2021.
  • Per Business Quant, the three most recent readings for VTAK's Current Deferred Revenue are $1.8 million (Q2 2021), $1.8 million (Q1 2021), and $1.8 million (Q4 2020).